William M. Sikov, MD, of Women and Infants Hospital, discusses abstract S4-05, "Impact of intrinsic subtype by PAM50 and other gene signatures on pathologic complete response rates in triple-negative breast cancer after neoadjuvant chemotherapy with or without carboplatin or bevacizumab: CALGB 40603/150709 (Alliance)."
Ismail Jatoi, MD, PhD, FACS, and Clifford A. Hudis, MD, FACS, discuss the role of ovarian suppression and hormonal therapy in premenopausal women.
Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses findings from abstract S3-02, “NSABP B-36: A randomized phase III trial comparing six cycles of fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients with node-negative breast cancer.”
William J. Gradishar, MD, of Northwestern University, and Edith A. Perez of the Mayo Clinic Cancer Center, discuss immunotherapy and the highlights of the BOLERO-1 and SOFT trials.
Jame Abraham, MD, FACP, of the Cleveland Clinic, offers his thoughts on abstract S1-09, "A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer," presented by Rita Nanda, MD.
Larry Wickerham, MD, and Charles E. Geyer, Jr., MD, FACP, take a closer look at the results from the NSABP B-36 and SOFT Trials.
